{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T17:18:44Z","timestamp":1781198324302,"version":"3.54.1"},"reference-count":52,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T00:00:00Z","timestamp":1599004800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Parkinson\u2019s disease (PD) is an age-related neurodegenerative disorder which is assessed based on the motor symptoms. A number of microRNAs (miRNAs) are dysregulated and involved in the pathogenesis or development of PD. However, no confirmed markers are used for the early detection of PD. The present study aimed to elucidate the potential two miRNAs (miR-132-3p and miR-146-5p) as novel markers for early PD diagnosis. In the present study, the expression levels of miR-132-3p and miR-146-5p in serum samples from 82 patients with PD and 44 healthy volunteers were measured by reverse transcription-quantitative polymerase chain reaction. Furthermore, the correlation analysis was performed between aberrant miRNAs and Braak staging, Part V of the Unified Parkinson\u2019s Disease Rating Scale (UPDRS-V; the modified Hoehn and Yahr staging of PD) and Part III of the UPDRS-III. Subsequently, the receiver\u2013operating characteristic (ROC) curve results of miR-132-3p and miR-146-5p from healthy volunteers for PD prediction and from severe PD patients were assessed. From the results it was observed that miR-132-3p and miR-146a-5p expressions were significantly decreased in the serum samples of patients with PD compared to those in the healthy volunteers. Moreover, the expressions of miR-132-3p and miR-146a-5p showed a dramatic decrease in severe PD patients as compared to the normal PD patients. Meanwhile, miR-132-3p and miR-146-5p expressions were negatively correlated with Braak staging (<jats:italic>r<\/jats:italic> = \u22120.45, <jats:italic>P<\/jats:italic> &lt; 0.0001; <jats:italic>r<\/jats:italic> = \u22120.51, <jats:italic>P<\/jats:italic> &lt; 0.0001), UPDRS-III (<jats:italic>r<\/jats:italic> = \u22120.55, <jats:italic>P<\/jats:italic> &lt; 0.0001; <jats:italic>r<\/jats:italic> = \u22120.51, <jats:italic>P<\/jats:italic> &lt; 0.0001) and UPDRS-V scores (<jats:italic>r<\/jats:italic> = \u2212 0.46, <jats:italic>P<\/jats:italic> &lt; 0.0001; <jats:italic>r<\/jats:italic> = \u22120.45, <jats:italic>P<\/jats:italic> &lt; 0.0001) in PD patients. The area under the curve (AUC) results of miR-132-3p and miR-146a-5p in discriminating PD patients from the healthy controls were 0.7325 (95% CI = 0.6400\u20130.8251) and 0.7295 (95% CI = 0.3658\u20130.8232). Moreover, the AUC results of miR-132-3p and miR-146-5p concerning discriminating severe PD patients from normal PD patients were 0.8175 (95% CI = 0.7229\u20130.9121) and 0.7921 (95% CI = 0.6937\u20130.8905). In other words, both miR-132-3p and miR-146a-5p may function as promising biomarkers for early diagnosis of PD.<\/jats:p>","DOI":"10.1515\/biol-2020-0060","type":"journal-article","created":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T13:01:33Z","timestamp":1599483693000},"page":"647-653","source":"Crossref","is-referenced-by-count":28,"title":["Aberrant expression of microRNA-132-3p and microRNA-146a-5p in Parkinson\u2019s disease patients"],"prefix":"10.1515","volume":"15","author":[{"given":"Yu","family":"Shu","sequence":"first","affiliation":[{"name":"Neurology Department, The Fourth Affiliated People\u2019s Hospital of Jiangsu University, Zhenjiang 212000, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjun","family":"Qian","sequence":"additional","affiliation":[{"name":"Neurology Department, The Fourth Affiliated People\u2019s Hospital of Jiangsu University, Zhenjiang 212000, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Wang","sequence":"additional","affiliation":[{"name":"Clinical Medicine, Jiangsu University, Zhenjiang 212013, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","reference":[{"key":"ref91","doi-asserted-by":"crossref","first-page":"37043","DOI":"10.18632\/oncotarget.6158","article-title":"Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease","volume":"6","year":"2015","journal-title":"Oncotarget"},{"key":"ref211","first-page":"9280170","article-title":"Circulating miR-132-3p as a candidate diagnostic biomarker for malignant mesothelioma","volume":"2017","year":"2017","journal-title":"Dis Markers"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3389\/fncel.2017.00170","article-title":"Reduced circulating levels of miR-433 and miR-133b are potential biomarkers for Parkinson\u2019s disease","volume":"11","year":"2017","journal-title":"Front Cell Neurosci"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.parkreldis.2014.10.026","article-title":"Parkinson\u2019s disease severity levels and MDS-unified Parkinson\u2019s disease rating scale","volume":"21","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson\u2019s disease","volume":"386","year":"2015","journal-title":"Lancet"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.parkreldis.2014.10.026","article-title":"Parkinson\u2019s disease severity levels and MDS-unified Parkinson\u2019s disease rating scale","volume":"21","year":"2015","journal-title":"Parkinsonism Relat Disord"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-7046-9_1","article-title":"MicroRNAs, long noncoding RNAs, and their functions in human disease","volume":"1617","year":"2017","journal-title":"Methods Mod Biol"},{"key":"ref231","first-page":"846501","article-title":"MicroRNA-146b-3p regulates retinal inflammation by suppressing adenosine deaminase-2 in diabetes","volume":"2015","year":"2015","journal-title":"Biomed Res Int"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","article-title":"MicroRNAs: target recognition and regulatory functions","volume":"136","year":"2009","journal-title":"Cell"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","article-title":"MicroRNAs: target recognition and regulatory functions","volume":"136","year":"2009","journal-title":"Cell"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s00221-017-4989-1","article-title":"MicroRNAs in Parkinson\u2019s disease","volume":"235","year":"2017","journal-title":"Exp Brain Res"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"101664","DOI":"10.1016\/j.pneurobio.2019.101664","article-title":"microRNA dysregulation in neurodegenerative diseases: a systematic review","volume":"182","year":"2019","journal-title":"Prog Neurobiol"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3233\/CBM-160319","article-title":"MicroRNA in breast cancer: the association with BRCA1\/2","volume":"19","year":"2017","journal-title":"Cancer Biomark"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nrg1990","article-title":"The evolution of gene regulation by transcription factors and microRNAs","volume":"8","year":"2007","journal-title":"Nat Rev Genet"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/mds.22875","article-title":"Progression of Parkinson\u2019s disease as evaluated by Hoehn and Yahr stage transition times","volume":"25","year":"2010","journal-title":"Mov Disord"},{"key":"ref491","first-page":"846501","article-title":"MicroRNA-146b-3p regulates retinal inflammation by suppressing adenosine deaminase-2 in diabetes","volume":"2015","year":"2015","journal-title":"Biomed Res Int"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nrg1990","article-title":"The evolution of gene regulation by transcription factors and microRNAs","volume":"8","year":"2007","journal-title":"Nat Rev Genet"},{"key":"ref501","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.nut.2015.06.008","article-title":"Expression of inflammation-related miRNAs in white blood cells from subjects with metabolic syndrome after 8 wk of following a mediterranean diet-based weight loss program","volume":"32","year":"2016","journal-title":"Nutrition"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"908","DOI":"10.2174\/156802661510150328223428","article-title":"Dopamine D3 agonists in the treatment or Parkinson\u2019s disease","volume":"15","year":"2015","journal-title":"Curr Top Med Chem"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/mds.22875","article-title":"Progression of Parkinson\u2019s disease as evaluated by Hoehn and Yahr stage transition times","volume":"25","year":"2010","journal-title":"Mov Disord"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","article-title":"Parkinson\u2019s disease","volume":"386","year":"2015","journal-title":"Lancet"},{"key":"ref301","first-page":"a008870","article-title":"Clinical approach to Parkinson\u2019s disease: features, diagnosis, and principles of management","volume":"2","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ensci.2018.09.002","article-title":"Differential expression of miRNA 155 and miRNA 146a in Parkinson\u2019s disease patients","volume":"13","year":"2018","journal-title":"eNeurologicalSci"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s12031-017-0926-9","article-title":"Plasma and while blood cells show different miRNA expression profiles in Parkinson\u2019s disease","volume":"62","year":"2017","journal-title":"J Mol Neurosci"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/cbf.3224","article-title":"Serum miR-221 as a biomarker for Parkinson\u2019s disease","volume":"34","year":"2016","journal-title":"Cell Biochem Funct"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.nut.2015.06.008","article-title":"Expression of inflammation-related miRNAs in white blood cells from subjects with metabolic syndrome after 8 wk of following a mediterranean diet-based weight loss program","volume":"32","year":"2016","journal-title":"Nutrition"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/ana.25490","article-title":"Meta-analyses identify differentially expressed micrornas in Parkinson\u2019s disease","volume":"85","year":"2019","journal-title":"Ann Neurol"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12918-019-0680-4","article-title":"miRNAs and target genes in the blood as biomarkers for the early diagnosis of Parkinson\u2019s disease","volume":"13","year":"2019","journal-title":"BMC Syst Biol"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3389\/fncel.2017.00170","article-title":"Reduced circulating levels of miR-433 and miR-133b are potential biomarkers for Parkinson\u2019s disease","volume":"11","year":"2017","journal-title":"Front Cell Neurosci"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12918-019-0680-4","article-title":"miRNAs and target genes in the blood as biomarkers for the early diagnosis of Parkinson\u2019s disease","volume":"13","year":"2019","journal-title":"BMC Syst Biol"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ensci.2018.09.002","article-title":"Differential expression of miRNA 155 and miRNA 146a in Parkinson\u2019s disease patients","volume":"13","year":"2018","journal-title":"eNeurologicalSci"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"908","DOI":"10.2174\/156802661510150328223428","article-title":"Dopamine D3 agonists in the treatment or Parkinson\u2019s disease","volume":"15","year":"2015","journal-title":"Curr Top Med Chem"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s10072-017-2841-9","article-title":"Plasma levels of miR-137 and miR-124 are associated with Parkinson\u2019s disease but not with Parkinson\u2019s disease with depression","volume":"38","year":"2017","journal-title":"Neurol Sci"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1007\/s00702-017-1799-3","article-title":"Advanced Parkinson\u2019s or \u201ccomplex pharse\u2019 Parkinson\u2019s disease? Re-evaluation is needed","volume":"124","year":"2017","journal-title":"J Neural Transm"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/cbf.3224","article-title":"Serum miR-221 as a biomarker for Parkinson\u2019s disease","volume":"34","year":"2016","journal-title":"Cell Biochem Funct"},{"key":"ref511","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1002\/ana.25490","article-title":"Meta-analyses identify differentially expressed micrornas in Parkinson\u2019s disease","volume":"85","year":"2019","journal-title":"Ann Neurol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3389\/fnagi.2017.00232","article-title":"MicroRNA-4639 is a regulator of DJ-1 expression and a potential early diagnostic marker for Parkinson\u2019s disease","volume":"9","year":"2017","journal-title":"Front Aging Neurosci"},{"key":"ref471","first-page":"9280170","article-title":"Circulating miR-132-3p as a candidate diagnostic biomarker for malignant mesothelioma","volume":"2017","year":"2017","journal-title":"Dis Markers"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s12031-017-0926-9","article-title":"Plasma and while blood cells show different miRNA expression profiles in Parkinson\u2019s disease","volume":"62","year":"2017","journal-title":"J Mol Neurosci"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"101664","DOI":"10.1016\/j.pneurobio.2019.101664","article-title":"microRNA dysregulation in neurodegenerative diseases: a systematic review","volume":"182","year":"2019","journal-title":"Prog Neurobiol"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3389\/fnagi.2017.00232","article-title":"MicroRNA-4639 is a regulator of DJ-1 expression and a potential early diagnostic marker for Parkinson\u2019s disease","volume":"9","year":"2017","journal-title":"Front Aging Neurosci"},{"key":"ref41","first-page":"a008870","article-title":"Clinical approach to Parkinson\u2019s disease: features, diagnosis, and principles of management","volume":"2","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3233\/CBM-160319","article-title":"MicroRNA in breast cancer: the association with BRCA1\/2","volume":"19","year":"2017","journal-title":"Cancer Biomark"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s00221-017-4989-1","article-title":"MicroRNAs in Parkinson\u2019s disease","volume":"235","year":"2017","journal-title":"Exp Brain Res"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"37043","DOI":"10.18632\/oncotarget.6158","article-title":"Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease","volume":"6","year":"2015","journal-title":"Oncotarget"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-7046-9_1","article-title":"MicroRNAs, long noncoding RNAs, and their functions in human disease","volume":"1617","year":"2017","journal-title":"Methods Mod Biol"},{"key":"ref341","first-page":"865","article-title":"MicroRNA in cardiovascular biology and disease","volume":"26","year":"2017","journal-title":"Adv Clin Exp Med"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1021\/acschemneuro.8b00460","article-title":"Altered expression levels of microRNA-132 and Nurr1 in peripheral blood of Parkinson\u2019s disease: potential disease biomarkers","volume":"10","year":"2019","journal-title":"ACS Chem Neurosci"},{"key":"ref441","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1007\/s00702-017-1799-3","article-title":"Advanced Parkinson\u2019s or \u201ccomplex pharse\u2019 Parkinson\u2019s disease? Re-evaluation is needed","volume":"124","year":"2017","journal-title":"J Neural Transm"},{"key":"ref81","first-page":"865","article-title":"MicroRNA in cardiovascular biology and disease","volume":"26","year":"2017","journal-title":"Adv Clin Exp Med"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s10072-017-2841-9","article-title":"Plasma levels of miR-137 and miR-124 are associated with Parkinson\u2019s disease but not with Parkinson\u2019s disease with depression","volume":"38","year":"2017","journal-title":"Neurol Sci"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1021\/acschemneuro.8b00460","article-title":"Altered expression levels of microRNA-132 and Nurr1 in peripheral blood of Parkinson\u2019s disease: potential disease biomarkers","volume":"10","year":"2019","journal-title":"ACS Chem Neurosci"}],"container-title":["Open Life Sciences"],"original-title":[],"link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/biol\/15\/1\/article-p647.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/downloadpdf\/journals\/biol\/15\/1\/article-p647.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T19:48:24Z","timestamp":1614455304000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/biol-2020-0060\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,2]]},"references-count":52,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.1515\/biol-2020-0060","relation":{},"ISSN":["2391-5412"],"issn-type":[{"value":"2391-5412","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,2]]}}}